Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, has published a new Spectrum report from the internationally respected Dr. Barrie G. James, president of Pharma Strategy Consulting, on the current and future status of the pharmaceutical industry. Dr. James maintains that if large pharmaceutical companies want to survive, they must make radical changes to many aspects of their business.

"For nearly 40 years, large, fully integrated pharmaceutical companies have dominated the industry as well as the hopes of analysts, management, and shareholders," said Dr. James. "However, the big pharma model is facing serious difficulties from weak pipelines, patent expirations, high-profile withdrawals, perceived high prices, and expensive promotional practices through manufacturing problems, accounting discrepancies, declining financial performance, and decreasing stock values. Clearly, the time has come for pharmaceutical companies to develop radically new ways to compete."

"By 2010, the only successful pharmaceutical companies will be the organizations that successfully adapt their strategies and create new business models which more closely reflect the new market realities, innovative technologies, customer demands, and the pricing environment facing the industry," continued Dr. James.

Decision Resources has organized a teleconference for those interested in hearing more about Dr. James's findings on the pharmaceutical business landscape. The teleconference will be on Tuesday, June 17 at 10:00 a.m. EST. For more information about the teleconference or to sign up to participate, please contact:

  For media:    Liz Marshall, Decision Resources, 781-296-2563   For other interested parties:    Frank Sama, Decision Resources, 781-296-2553.    About Spectrum from Decision Resources 

Spectrum is a comprehensive executive advisory service that identifies and analyzes key business and technology drivers of the pharmaceutical and biotechnology markets. A mix of publications, telephone inquiry access, and teleconferences provides an "over the horizon" perspective for decision makers wrestling with complex issues and opportunities. Spectrum's analysis and research is organized into the following report portfolios:

  * Pharmaceutical Industry Dynamics   * Therapy Markets and Emerging Technologies   * Diagnostics and Related Technologies   * Pharmacoeconomics, Pricing, and Reimbursement   * Drug Discovery and Design   * Drug Delivery and Reformulation Technologies    About Decision Resources 

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Hepatitis C Drug Market to Grow from $2.5 Billion in 2002 to More Than $9 Billion in 2012

View Now